Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022

Ads

You May Also Like

Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA

VANCOUVER, British Columbia, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), ...

Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology

              Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology Inked ...